Skip to content

Author

V. Herranz-Pérez

We have 2 of 75 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Intracranial Targeting of Cholesterol Processing Reveals a Therapeutic Vulnerability that Reprograms Glioblastoma and Promotes Antitumor Immunity

These findings establish cholesterol dysregulation–induced metabolic collapse as a promising therapeutic approach for GBM using two FDA-approved drugs: the H1 histamine antagonist clemastine and the retinoid X receptor agonist bexarotene.

Maria J. Ulloa-Navas, Rachel M. Whitehead, Vanessa K. Jones et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.